Skip to main content
Clinical Trials/JPRN-jRCT1051210070
JPRN-jRCT1051210070
Recruiting
未知

Prospective observational study of the effect of romosozumab in postmenopausal osteoporotic women with inadequate response to existing osteoporosis treatment - Prospective observational study of the effect of romosozumab in postmenopausal osteoporotic women with inadequate response to existing osteoporosis treatment

Yamamoto Misa0 sites20 target enrollmentAugust 24, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Osteoporosis, Postmenopausal
Sponsor
Yamamoto Misa
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 24, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Yamamoto Misa

Eligibility Criteria

Inclusion Criteria

  • Patients with postmenopausal osteoporosis who have been treated with bisphosphonates or denosumab at our department for at least one year, but whose bone mineral density values of lumbar spine or femur by DXA method are less than 70% of YAM (Young Adult Mean) will be included.
  • Bone mineral density will be measured by measuring the bone mineral density of the lumbar spine and femur by the double X\-ray absorptiometry (DXA method) using a bone mineral density measurement device (Discovery A Hologic) installed at our hospital. The diagnosis shall be based on the therapeutic intervention criteria set forth by the Japanese Society of Osteoporosis and shall meet the following diagnostic criteria.
  • The criteria for the diagnosis of osteoporosis are as follows:
  • 1\) For patients with fragility fractures, 1:there must be a vertebral fracture or a proximal femoral fracture 2: There must be other fragility fractures and the bone density must be less than 80% of the YAM.
  • 2\) In the absence of a fragility fracture, bone density should be less than 70% of the YAM or less than \-2\.5 SD.
  • The cause of osteoporosis is not limited to postmenopausal osteoporosis, but also includes osteoporosis associated with hormone decline after cancer treatment.

Exclusion Criteria

  • (1\) Patients with a history of hypersensitivity to components of sclerostin products.
  • (2\) Patients with hypocalcemia.
  • (3\) Patients who are judged by the physician in charge to be inappropriate for this study for other reasons.

Outcomes

Primary Outcomes

Not specified

Similar Trials